P/E ratio for Athersys (ATHX)

P/E ratio history for Athersys from 2007 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Amgen AMGN	18.8	-421,945.16%	🇺🇸 USA
Pfizer PFE	14.2	-319,028.50%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.5	-326,024.43%	🇺🇸 USA
Moderna MRNA	-4.46	99,991.35%	🇺🇸 USA
Johnson & Johnson JNJ	10.4	-233,398.54%	🇺🇸 USA
United States Lime & Minerals USLM	10.1	-226,627.06%	🇺🇸 USA
Arena Pharmaceuticals ARNA	N/A	N/A	🇺🇸 USA
Merck MRK	54.9	-1,232,911.50%	🇺🇸 USA
Sanofi SNY	15.4	-345,490.48%	🇫🇷 France

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.